Thread–Datavant partnership launches solution to link real world and clinical trial data

Thread announces expansion of Datavant partnership with launch of configurable tokenization feature to connect clinical trial and real-world data securely and compliantly for enhanced evidence generation.

Thread^®, provider of a decentralized healthcare research platform, has announced the addition of a fully configurable tokenization feature that securely and compliantly connects clinical trial and real-world data (RWD). This advancement is powered by Datavant’s suite of privacy-centric data connectivity tools and will enable access to clinical trial participants’ longitudinal health journeys, enhancing evidence generation.  

The incorporation of the Datavant-driven new tokenization feature into Thread’s flagship decentralized research platform builds on a collaboration established earlier in 2023. Datavant’s connectivity tools enable clients to tokenize, match, and link patient records across de-identified datasets, while preserving patient privacy in compliance with regulations. By engaging these tools to connect clinical trial data with RWD, biopharmaceutical companies can generate, and integrate into analyses, longitudinal real-world views of clinical trial participants’ healthcare journeys. This advanced research data access, in an expanded clinical trial landscape, and resultant deeper understanding of patient outcomes have the power to unlock the full potential of studies.  

“Thread’s enhanced tokenization feature, backed by Datavant’s leading de-identification technology, is a powerful shift in the way RWD can be integrated into clinical trials. Our customers can now gain and integrate their clinical and RWD in a few clicks to support their goal of generating additional evidence,” said Thread co-founder and CEO John Reites.   

Thread’s new feature enhances its platform to enable clients to:  

• Easily configure their studies to include tokenization by toggling a switch in Thread’s no-code study builder  
• Seamlessly gain patient consent to connect their de-identified data via a single device and user flow  
• Securely connect clinical trial data to RWD from claims, electronic health records and other secondary sources, while preserving patient privacy  
• Generate insights into the study participant’s real-world healthcare journey outside of the clinical trial  

“Linking clinical trial data with RWD can yield enormous benefits for both life sciences researchers and patients, by generating better evidence on treatment safety and efficacy while reducing the burden on trial participants,” said Tal Rosenberg, President and General Manager, Life Sciences, Ecosystem & Public Sector at Datavant. “We’re thrilled to enhance our use case by embedding Datavant’s technology onto Thread’s no-code platform and offering the power of connected clinical trials to a broader customer base.”